The pairing between Sanofi Genzyme and Maker Faire Rome is confirmed. Once again, innovation goes right to the heart
To stimulate and reward innovations that get right to the heart of the needs of people with disabilities. To support these people, and ensure they have future. This is the ambition of Make to Care, the contest conceived last year by Sanofi Genzyme to capitalize on ideas to help improve the daily life of people with serious diseases and their family members, making its return on the occasion of the Fifth Edition of Maker Faire Rome – The European Edition 4.0 (01-03 December, Fiera di Roma).
Of all the ideas and designs that will register by 15 September in the healthcare & wellness section of the new Call for Makers, the Assessment Committee chaired by Giuseppe Novelli – Rector of Università degli Studi di Roma Tor Vergata – will select the initiatives that are most innovative and original in proposing concrete solutions to improve the daily lives of people living with any form of disability, and of those caring for them.
“I am glad to be able to repeat my participation in Make to Care as chairman of the Assessment Committee,” says Professor Novelli. “This project has the merit of bringing out Italian excellence and the talents coming out of our universities that can grasp a tangible need linked to the patients’ daily life, and commit their creativity and entrepreneurial spirit to providing effective responses. The experience of the first edition was an exciting one, and I’m sure we’ll find interesting and ambitious designs again this year.”
Participation in the contest is free of charge and open to everyone (natural persons in Italy or abroad, companies, bodies, associations, foundations, and/or other legal persons, with residence or main office in Italy or in another country of the European Union) who, in line with the philosophy of the Maker community, have managed to grasp a tangible need, orienting their own ingenuity and proposing an innovative solution.
The finalists will take part in Make to Care’s closing evening to be held in Rome on 29 November during an event leading up to the start of the Fifth Edition of Maker Faire Rome. Each will be given five minutes to present their ideas, beat the competition, and claim victory.
At this event, Polifactory – the makerspacefablab at Politecnico di Milano – on behalf of the Fondazione Politecnico and as technical/scientific partner for the new edition of the contest, will present the first report on the ecosystem of innovation for disability: a major new development this year is the collaboration protocol signed between Sanofi Genzyme and the Fondazione.
All the finalist designs will be guests at Maker Faire Rome – The European Edition 4.0, from 01 to 3 December at Fiera di Roma.
As a reward, the top-two designs will have the opportunity to enjoy an experience in Silicon Valley, and to visit some enterprises in the pulsing heart of innovation: companies doing fast prototyping and 3D printing, and brilliant, young start-ups aiming to revolutionize the health and wellness sector thanks to new technologies, big data, and collaborations with universities and Internet giants. And then there are the fablabs, incubators, and coworking spaces: a set of stimuli and opportunities for dialogue that can give rise to productive synergies and future collaborations – and that can open new horizons to respond to the needs of those living with a disability. This opportunity will be managed thanks to collaboration with Aster, a research and innovation company in the Emilia Romagna Region, and its unit in the United States.
Visit the Make to Care website for information on how to take part, along with the regulations and criteria for inclusion. And to stay up-to-date, follow the contest on the official Facebook page and don’t forget the hashtag #MakeToCare!
Sanofi, a global leader in health and research, develops and distributes therapeutic solutions focusing on patients’ needs. Sanofi Genzyme is Sanofi’s specialty care division, on the cutting edge in the research and development of therapies for disabling pathologies that are hard to diagnose and treat. In addition to rare diseases, it now offers answers in the area of multiple sclerosis, oncology and – in the near future – immunology.